HC Wainwright Issues Positive Forecast for Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price
5 Articles
5 Articles
HC Wainwright Issues Positive Forecast for Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price
HC Wainwright increased their price target on shares of Iovance Biotherapeutics from $9.00 to $20.00 and gave the company a "buy" rating in a research report on Tuesday.
The shares Iovance Biotherapeutics (IOVA) recorded a jump of 33,26% and touched the maximum for two years, with the title at $ 14.64. The opening at 12.79 immediately left room for a maximum intraday of 15,30. To trigger the rally, the guide on revenues 2026 raised at $ 410
Iovance Biotherapeutics stock surges 33% after guidance hike, RSI flashes overbought
Iovance Biotherapeutics, Inc. stock is surging, trading at $14.645 as of 14:07 ET on September 29, 2026, up 33.26% from a $10.99 close. The catalyst is the company’s raised 2026 revenue guidance to $410–$420 million, driven by demand for Amtagvi and Proleukin . IOVA - daily chart with candlesticks,...
Iovance Biotherapeutics Stock Soars 20% After Cancer Therapy Maker Raises 2026 Revenue Forecast Sharply
Iovance Biotherapeutics shares rose more than 20% after the company raised its 2026 revenue forecast, citing accelerating demand for its melanoma therapy Amtagvi.
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
